After Hours
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities.
Stocks Info
As a NYSE listed company, GMED falls under the Healthcare sector while operating within the Medical Devices industry segment. The current market capitalization of Globus Medical Inc is $10.74B. A total of 0.81 million shares were traded on the day, compared to an average of 1.14M shares.
Insider Activity
Aside from predicting where a stock will go, investors also consider insider trades as an indicator of the stock’s future direction. During the recent three months, GMED has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 0 BUYs and 0 SELLs from insiders. Insiders purchased 0 shares during that period but sold 0.
In the most recent transaction, RHOADS ANN D sold 7,500 shares of GMED for 78.68 per share on Feb 28 ’25. After the transaction, the Director now owns 35,384 company shares. In a previous transaction on Feb 28 ’25, RHOADS ANN D bought 7,500 shares at 78.67 per share.
Among the insiders who sold shares, Pfeil Keith W disposed of 14,167 shares on Jan 10 ’25 at a per-share price of $88.29. This resulted in the COO, CFO holding 0 shares of GMED after the transaction. In another insider transaction, Pfeil Keith W bought 14,167 shares at $88.29 per share on Jan 10 ’25.
In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. According to analysts who have offered 12-month price targets for GMED in the last 3 months, the mean price target is $98.69 with high estimates of $115.00 and low estimates of $90.00. In terms of 52-week highs and lows, GMED has a high of $94.93 and a low of $49.33.
As of this writing, GMED has an earnings estimate of $0.76 per share for the current quarter. EPS was calculated based on a consensus of 15.0 estimates, with a high estimate of $0.81 per share and a lower estimate of $0.7.
Balance Sheet Annually/Quarterly
The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. GMED’s latest balance sheet shows that the firm has $443.45M in Cash & Short Term Investments as of fiscal 2021. Its Book Value Per Share was $30.40, while its Total Shareholder’s Equity was $1.74B.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for GMED is Buy with a score of 4.27.
